Leqembi Pen launches in Japan, second market for at-home dosing
STOCKHOLM — November 13, 2026 -- Eisai has launched Leqembi Pen, a once-weekly subcutaneous form of lecanemab for early Alzheimer's disease, in Japan. The launch comes 58 days after the September 16, 2026 approval, BioArctic said. Japan is the second country after the US where the subcutaneous formulation is on sale.
Leqembi Pen enters Japan's NHI price list as a 500 mg weekly dose
The product is now on Japan's National Health Insurance (NHI) Drug Price List. The approved dose is 500 mg once a week, given through two autoinjector pens. By FairsOnline's calculation, that is 52 doses and 104 pens a year. The intravenous (IV) option, given every two weeks in a medical facility, works out to 26 infusion visits a year at that interval. The release did not disclose the NHI price.